Comparison of Myeloid Antigen Expression in B-Lineage ALL Patients With and Without TEL/AML1 Gene Expression (ALL-AIEOP95 and ALL-BFM95)
| . | TEL/AML1 Positive . | TEL/AML1 Negative . | |||
|---|---|---|---|---|---|
| . | n = 61* . | n = 199* . | |||
| . | . | . | . | . | |
| My-positive† | 15 | 24.6% | 6 | 3.0% | P < .01 |
| My-negative | 46 | 75.4% | 193 | 97.0% | |
| . | TEL/AML1 Positive . | TEL/AML1 Negative . | |||
|---|---|---|---|---|---|
| . | n = 61* . | n = 199* . | |||
| . | . | . | . | . | |
| My-positive† | 15 | 24.6% | 6 | 3.0% | P < .01 |
| My-negative | 46 | 75.4% | 193 | 97.0% | |
Immunological data on the coexpression of myeloid antigens was available in 61 of 63 (96.8%) TEL/AML1-positive cases and in 199 of 217 (91.7%) TEL/AML1-negative ALL cases.
As defined by the expression of at least two of the following antigens: CD13, CD33, and CDw65, in more than 20% of the gated blast cell population.